Inhaled corticosteroids and the increased risk of pulmonary tuberculosis: a population-based case-control study

Chung, Wei‐Sheng; Chen, Y.-F.; Hsu, Jin-Chyr; Yang, Wen Ta; Chen, S.-C.; Chiang, John Y.

doi:10.1111/ijcp.12459

Cited by 24 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall ICS use caused a 2.04‐fold increased risk of developing TB. Interestingly, it appeared from this study that high doses of ICS place the patient at a risk level (OR 2.32) similar to that found in those receiving disease modifying anti‐rheumatic drugs such as anti‐TNFα . Chung's study actually confirms another recent cohort study conducted in South Korea from a large database of the Health Insurance Review and Assessment Service although the risk was somewhat lower in the latter with an odd ratio for TB diagnosis of 1.2 in those receiving ICS whichever the underlying obstructive disease .…”

supporting

confidence: 77%

Time for reasoning ICS prescription in obstructive airway diseases

Louis

Demarche

2014

Int J Clin Pract

View full text Add to dashboard Cite

show abstract

supporting

confidence: 77%

Time for reasoning ICS prescription in obstructive airway diseases

Louis

Demarche

2014

Int J Clin Pract

View full text Add to dashboard Cite

show abstract

“…The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM), was used for the diagnosis codes. The reliability of epidemiologic studies used in LHID2000 has been reported in our previous studies …”

Section: Methodsmentioning

confidence: 99%

“…The reliability of epidemiologic studies used in LHID2000 has been reported in our previous studies. 21,22…”

Section: Data Sourcementioning

confidence: 99%

Inhaled corticosteroids and the risks of low‐energy fractures in patients with chronic airway diseases: A propensity score matched study

Tsai

Liao

Lin

et al. 2017

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

“…In terms of side-effects, a greater increase in the risk of pneumonia related to ICS was found in current smokers, and patients with prior pneumonia, body mass index <25 kg/m 2 and severe airflow limitation (51). Beyond intrinsic patients’ characteristics, environmental factors may also influence the benefit-risk ratio of ICS, as recently suggested for the ICS-associated risk of tuberculosis, which is greater in countries with high incidence of tuberculosis (52). …”

Section: Positioning Current Therapeutic Options – the Gold (R)evolutionmentioning

confidence: 99%

Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management

et al. 2015

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a common, complex and heterogeneous condition which is responsible for considerable and growing morbidity, mortality and healthcare expense worldwide. In order to decipher the complexity of COPD, it is imperative that we identify groups of patients with similar clinical characteristics, prognosis and/or therapeutic needs, so called clinical phenotypes. This strategy is logical for research but it may be of limited clinical value because clinical phenotypes may overlap in the same patient and the same clinical phenotype could result from different biological mechanisms. With the goal of matching assessment to treatment choices, the most recent iteration of GOLD reorganized treatment objectives into two categories (improving symptoms, i.e., dyspnoea and health status, and decreasing future risk, as predicted by FEV1 level and exacerbations history), thus moving closer to individualized medicine using currently available bronchodilators and anti-inflammatory medications. Yet, future therapeutic options are likely to include targeting endotypes which reflect subtypes of patients defined by a distinct pathophysiological mechanism. Specific biomarkers of these endotypes would be particularly useful for clinical practice, especially when clinical phenotype alone is insufficient to identify the underlying endotype. Currently, a limited series of potential COPD endotypes and biomarkers have been suggested. We will gain empiric knowledge from proof of concept trials in COPD with emerging drugs that target specific inflammatory pathways. In each instance, specific endotyping and biomarker efforts will likely be required for success of these trials, since the pathways are likely to be operative in only a subset of patients. Network analysis of human diseases offers the possibility of a better understanding of disease patho-biologic complexity while facilitating the development of new therapeutic alternatives and, importantly, a reclassification of complex diseases. All these development should pave the way towards personalized treatment of COPD in the clinic.

show abstract

Inhaled corticosteroids and the increased risk of pulmonary tuberculosis: a population-based case-control study

Abstract: Long-term ICS use may increase the risk of TB.

Cited by 24 publications

References 25 publications

Time for reasoning ICS prescription in obstructive airway diseases

Time for reasoning ICS prescription in obstructive airway diseases

Inhaled corticosteroids and the risks of low‐energy fractures in patients with chronic airway diseases: A propensity score matched study

Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management

Contact Info

Product

Resources

About